Basic Information
ID DDInter210
Drug Type small molecule
Molecular Formula C17H15BrF2N4O3
Molecular Weight 441.233
CAS Number 606143-89-9
Description Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib] [A34275,L3335]. On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.[L3335]
ATC Classification L01EE03
IUPAC Name 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide
InChI ACWZRVQXLIRSDF-UHFFFAOYSA-N
Canonical SMILES CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
Useful Links DrugBank ChEBI PubChem Substance ChemSpider PharmGKB Wikipedia ChEMBL ZINC
Interactions with Binimetinib
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note